A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients by Ruben T. H. M. Larue et al.
STUDY PROTOCOL Open Access
A phase 1 ‘window-of-opportunity’ trial
testing evofosfamide (TH-302), a
tumour-selective hypoxia-activated
cytotoxic prodrug, with preoperative
chemoradiotherapy in oesophageal
adenocarcinoma patients
Ruben T. H. M. Larue1†, Lien Van De Voorde1*†, Maaike Berbée1, Wouter J. C. van Elmpt1, Ludwig J. Dubois1,
Kranthi M. Panth1, Sarah G. J. A. Peeters1,2, Ann Claessens1, Wendy M. J. Schreurs3, Marius Nap4,
Fabiënne A. R. M. Warmerdam5, Frans L. G. Erdkamp5, Meindert N. Sosef6,7 and Philippe Lambin1
Abstract
Background: Neo-adjuvant chemoradiotherapy followed by surgery is the standard treatment with curative intent
for oesophageal cancer patients, with 5-year overall survival rates up to 50 %. However, patients’ quality of life is
severely compromised by oesophagectomy, and eventually many patients die due to metastatic disease.
Most solid tumours, including oesophageal cancer, contain hypoxic regions that are more resistant to
chemoradiotherapy. The hypoxia-activated prodrug evofosfamide works as a DNA-alkylating agent under these hypoxic
conditions, which directly kills hypoxic cancer cells and potentially minimizes resistance to conventional therapy. This
drug has shown promising results in several clinical studies when combined with chemotherapy. Therefore, in this phase
I study we investigate the safety of evofosfamide added to the chemoradiotherapy treatment of oesophageal cancer.
Methods/Design: A phase I, non-randomized, single-centre, open-label, 3 + 3 trial with repeated hypoxia PET imaging,
will test the safety of evofosfamide in combination with neo-adjuvant chemoradiotherapy in potentially resectable
oesophageal adenocarcinoma patients. Investigated dose levels range from 120 mg/m2 to 340 mg/m2. Evofosfamide
will be administered one week before the start of chemoradiotherapy (CROSS-regimen) and repeated weekly up to a
total of six doses. PET/CT acquisitions with hypoxia tracer 18F-HX4 will be made before and after the first administration
of evofosfamide, allowing early assessment of changes in hypoxia, accompanied with blood sampling to measure
hypoxia blood biomarkers. Oesophagectomy will be performed according to standard clinical practice.
Higher grade and uncommon non-haematological, haematological, and post-operative toxicities are the primary
endpoints according to the CTCAEv4.0 and Clavien-Dindo classifications. Secondary endpoints are reduction in hypoxic
fraction based on 18F-HX4 imaging, pathological complete response, histopathological negative circumferential resection
margin (R0) rate, local and distant recurrence rate, and progression free and overall survival.
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Discussion: This is the first clinical trial testing evofosfamide in combination with chemoradiotherapy. The
primary objective is to determine the dose limiting toxicity of this combined treatment and herewith to
define the maximum tolerated dose and recommended phase 2 dose for future clinical studies. The addition
of non-invasive repeated hypoxia imaging (‘window-of-opportunity’) enables us to identify the biologically
effective dose. We believe this approach could also be used for other hypoxia targeted drugs.
Trial registration: ClinicalTrials.gov Identifier: NCT02598687.
Keywords: Oesophageal cancer, Neoadjuvant chemoradiotherapy, Evofosfamide, Oesophagectomy, Dose
limiting toxicity, Hypoxia imaging, Window-of-opportunity trial
Abbreviations: 18F-HX4, [18F]-fluortanidazole; AUC, Target area under the concentration-time curve in mg/ml/min;
CAIX, Carbonic anhydrase IX; CRM, Circumferential resection margin; CROSS, ChemoRadiotherapy for Oesophageal
cancer followed by Surgery Study; CT, Computed tomography; CTCAE, Common toxicity criteria for adverse events;
DLT, Dose-limiting toxicity; ECG, Electrocardiogram; EUS, Endoscopic ultrasound; FDG, [18F]-fluordeoxyglucose;
MTD, Maximum tolerated dose; nCRT, Neo-adjuvant chemoradiotherapy; OPN, Osteopontin; OS, Overall survival;
pCR, Pathological complete remission; PET, Positron emission tomography; PICC, Peripherally inserted central catheter;
RP2D, Recommended phase 2 dose; TH-302, Former abbreviation for evofosfamide; WHO, World Health Organisation
Background
The incidence of oesophageal cancer in developed Western
countries has risen in recent decades [1]. Adenocarcinoma
is now more prevalent than squamous cell carcinoma, with
most tumours located in the distal oesophagus. A Western
lifestyle is a risk factor and the disease is associated with
obesity and symptomatic gastro-oesophageal reflux [2].
The standard treatment with curative intent for T2 or
higher stage tumours consists of neoadjuvant chemora-
diotherapy (nCRT) followed by surgery, [3] as confirmed
by the Dutch ChemoRadiotherapy for Oesophageal cancer
followed by Surgery Study (CROSS) [4]. In this study,
significantly better 5-year overall survival (OS) rates were
observed for patients treated with nCRT followed by sur-
gery (47 %; 95 % CI 39–54) when compared to surgery
alone (33 %; 95 % CI 26–40), with greater benefits for
squamous cell carcinoma (61 % vs. 30 %) than for adeno-
carcinoma (43 % vs. 33 %) [5]. However, little progress has
been made in long-term survival (median OS ~49 months)
and the patients’ quality of life is still severely compro-
mised by the impact of oesophagectomy. Therefore, there
is an urgent need for new innovative treatment strategies.
The role of the tumour microenvironment in cancer
progression, and especially the difference between this
microenvironment and surrounding normal tissue, is a
subject of increasing investigational interest with a spe-
cific focus on hypoxia. Hypoxic tumour cells promote a
more aggressive phenotype, are associated with increased
metastatic potential, and are known to be more resistant
to standard chemoradiotherapy [6–14]. Recently, even
micro-metastases have been shown to exhibit hypoxia
[15]. Up to 5–10 % of the oesophageal cancer patients
suffer from progressive disease with metastases shortly
after completion of neoadjuvant chemoradiotherapy [16]
and the majority of patients eventually die because of meta-
static disease. Therefore, hypoxia is an attractive target for
newly developed drugs to increase the therapeutic effect of
conventional oesophageal cancer treatment modalities.
Evofosfamide (TH-302) is a hypoxia-activated prodrug
only activated under low levels of oxygen (hypoxia)
[17–23]. Evofosfamide exploits the activation of a nitroi-
midazole prodrug by a process that involves the reduction
of one electron, mediated by ubiquitous cellular reduc-
tases as the NADPH cytochrome P450 reductase to gener-
ate a radical anion prodrug. In the presence of oxygen
(normoxia) the radical anion prodrug reacts rapidly with
oxygen to produce superoxide and re-generate the original
prodrug. Under the low-oxygen conditions of the hypoxic
zones in tumours, however, the radical anion form of the
prodrug has a longer half-life and can either fragment
directly, or undergo further reductions, releasing the
active drug bromo-isophosphoramide mustard that acts
as a DNA cross-linker.
Recently, our group reported the radio-sensitizing effect
of evofosfamide in a preclinical setting using syngeneic
rat R1 rhabdomyosarcoma and human H460 NSCLC
(non-small cell lung cancer) xenograft tumour models.
Evofosfamide treatment significantly reduced the hyp-
oxic fraction, by more than 80 % compared to the control
tumours in both tumour models. This was visualized at
either micro-regional level or on PET images with the
hypoxia tracer 18F-HX4 (Fig. 1). Treatment with evofosfa-
mide alone caused a significant delay in tumour growth
while, when combined with radiotherapy (8 Gy), the
growth delay was further enhanced. In addition, hypoxic
fractions determined by pre-treatment 18F-HX4 scans
were predictive for the response associated with evofosfa-
mide treatment. Therefore, a pre-treatment 18F-HX4 scan
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may be beneficial for selection of patients for evofosfamide
treatment and a post treatment 18F-HX4 scan enables to
monitor treatment efficacy [20].
Evofosfamide has already been clinically investigated
both as monotherapy and in combination with chemo-
therapy or other targeted cancer drugs in over 1,500
patients, and is currently under investigation in more
than fifteen clinical trials registered at clinicaltrials.gov.
Investigated tumours include soft tissue sarcoma, pan-
creatic cancer, non-small cell lung cancer, melanoma,
and haematological malignancies. In general, the drug
is well tolerated with main toxicities being higher-grade
skin and mucosal toxicities, in particular in doses above
240 mg/m2 [24, 25]. In patients with advanced pancre-
atic cancer or soft-tissue sarcoma the combination of
chemotherapy with evofosfamide achieved favourable
outcomes, [26, 27] leading to two phase III clinical trials
(NCT01746979 and NCT01440088). Despite the promis-
ing pre-clinical results demonstrating the potential added
value of evofosfamide in combination with radiotherapy
[20], to date no clinical studies have been performed to
confirm this.
The primary objective of this 3 + 3 dose escalation
phase I ‘window-of-opportunity’ trial is to investigate the
safety of evofosfamide in combination with the standard
CROSS regimen in patients with distal oesophageal and
oesophago-gastric junction adenocarcinoma, to determine
the dose-limiting toxicities (DLTs) of the combined regi-
men and consequently to find the maximum tolerated
dose (MTD) and recommended phase II dose (RP2D).
As 18F-HX4 has shown to be a hypoxia PET-tracer
[28–35] with good repeatability in oesophageal cancer
[36], two 18F-HX4 PET-scans will be performed to
characterize tumour hypoxia at baseline and visualize
the potential change in hypoxia after the first admin-
istration of evofosfamide [9, 37].
Methods/Design
Study design
This is a phase I, non-randomized, single-centre, open-
label, 3 + 3, ‘window-of-opportunity’ trial combining
preoperative evofosfamide with the CROSS regimen
(NCT02598687).
In this traditional 3 + 3 dose-escalation design [38, 39],
a cohort of three patients will enter a given dose level,
and if no dose limiting toxicity (DLT) is observed 30 days
after surgery, the trial will proceed to the next dose level.
If a DLT occurs in 1 of 3 patients at a given dose level, 3
additional patients will be added to the same dose level
cohort. If the occurrence of DLT remains limited to 1
out of 6 patients, the trial will proceed to the next dose
level. If a DLT occurs in 2 or more patients at a certain
dose level, dose escalation will be stopped. The previous
dose level is then considered the maximum tolerated
dose (MTD) and, therefore, the recommended dose for a
phase II study. This is also summarized in Fig. 2. In this
study three dose levels will be tested, which means
that a maximum of nine to eighteen patients will be
included.
In- and exclusion criteria
Prior to treatment, patients are discussed at the centralized
multidisciplinary tumour board consisting of, inter alia, a
surgeon, medical oncologist, nuclear medicine physician
and radiation oncologist. Potentially curable patients with
histologically proven stage IB-IIIC T2-4 distal oesophageal
or oesophago-gastric junction adenocarcinoma are eligible
to participate in this study. The minimum age is 18 years
and the patients need to be fit for chemoradiotherapy
with a normal baseline electrocardiogram (ECG) and a
performance status of 0–2 according to the World
Health Organisation (WHO) classification.
The most important exclusion criteria are: a history of
thoracic radiotherapy, recent severe cardiac or pulmonary
disease, pregnancy, and/or viral infection.
Study treatment
All patients will receive nCRT according to the CROSS
regimen (Carboplatin AUC = 2 mg/ml/min, Paclitaxel
50 mg/m2, concurrent radiotherapy 41.4 Gy/23 frac-
tions) [4]. One starting dose of evofosfamide will be ad-
ministered one week prior to the start of the nCRT,
after which five additional administrations will be given
Fig. 1 Evofosfamide decreases the hypoxic fraction in a Rhabdomyosarcoma rat model. PET-scans with hypoxia tracer 18F-HX4 were made before
(day 0) and after (day 4) administering evofosfamide for four consecutive days at a dose of 25 mg/kg
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weekly on the same day as Carboplatin and Paclitaxel,
but 2–4 h prior to the chemotherapeutics (Fig. 3). The
drugs will be administered via a peripherally inserted
central catheter (PICC) and an ECG will be made be-
fore and after administration of the first two fractions
of evofosfamide. Investigated dose levels range from
120 mg/m2 to 340 mg/m2 evofosfamide, with the possibility
to de-escalate to a dose level of 60 mg/m2 (Fig. 2). Due to
the activation of evofosfamide under all hypoxic conditions,
the patients will receive extra skin-care, e.g. by using cold
packs during administration, to reduce hypoxia and prevent
the possible occurrence of any severe skin-toxicities.
Surgical resection will be attempted six to ten weeks
after completion of the nCRT, depending on the patient’s
characteristics and the lack of evidence for metastatic
disease on a re-evaluation FDG-PET/CT-scan made before
the planned surgery. Depending on tumour location and
general comorbidity, either a minimally invasive transhiatal
approach, including a one-field and low mediastinal lymph
node dissection, or a transthoracic approach with a two-
field lymph node dissection will be performed. The patho-
logical tumour response of the resected specimen will
be evaluated using the standardized pathology protocol,
reporting, amongst others, the tumour regression grade
according to the Mandard scoring [40], and the status
of the resected lymph nodes and resection margins.
Imaging
Standard non-invasive diagnostic modalities include
a (whole-body) FDG-PET/CT scan and/or endoscopic
Fig. 3 Study treatment schedule. Prior to the start of the standard CROSS treatment, patients will receive additional 18F-HX4 scans before and
after the first dose of evofosfamide
Fig. 2 Flowcharts summarizing the 3 + 3 dose escalating study design. In the first cohort of patients evofosfamide will be administered at a dose
of 120 mg/m2. Depending on the observed toxicity, we will escalate to dose level 2, or de-escalate to dose level -1. In further dose levels we can
only escalate to the next dose (up to 340 mg/m2) or stop due to dose limiting toxicity
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ultrasound (EUS) with biopsy. Patients that are included
in this study will receive two additional PET/CT-scans
with the hypoxia tracer 18F-HX4: the first scan at baseline
and the second scan three days after the first administra-
tion of evofosfamide (Fig. 3). 18F-HX4 will be administered
via a bolus intravenous injection 444 MBq (12 mCi), and
the PET/CT-scan will be acquired 4 h post injection. The
detailed acquisition protocol was previously described
by Zegers et al. [33]. Based on the available diagnostic
information, only a single bed position centred around
the primary tumour site will be imaged and a slice-
thickness of 3 mm will be used for the CT-reconstruction
[28, 29, 33, 34]. On both days a blood sample (5–7 ml) will
be drawn before administration of 18F-HX4 to analyse the
concentration of hypoxia related blood biomarkers car-
bonic anhydrase IX (CAIX) and osteopontin (OPN) [41].
Study parameters and endpoints
The main study endpoint is to determine the DLT and
define the MTD and RP2D. DLT is defined as:
– Uncommon grade 3 or higher non-haematological
toxicity according to the Common Terminology
Criteria for Adverse Events (CTCAE) version 4.0.
Grade III esophagitis in 50 % of the patients is
accepted.
– Grade 4 or higher haematological toxicity according
to CTCAE version 4.0.
– Grade 4 or higher postoperative toxicity within
30 days post-surgery according to the Clavien-Dindo
classification [42]. For anastomotic leakage and
cardiorespiratory complication we accept a rate of
50 % and 40 % respectively.
– Any grade 2 or higher non-haematological toxicity
that does not resolve to grade 0 or 1 toxicity by the
start of the next cycle, which is considered a DLT
according to the judgement of the investigator or
sponsor.
– Inability to begin the next cycle of treatment within
two weeks of the last dose due to unresolved
toxicity.
Secondary endpoints include investigating the change
in hypoxia based on 18F-HX4 imaging and blood bio-
markers to explore what would be the biologically effective
dose, and anti-tumour activity measured by the rate of
pathological complete response (pCR), histopathological
negative circumferential resection margin (CRM) rate, local
and distance recurrence rate, and progression free and
overall survival.
Post-treatment
End of treatment is defined as the date of the last radio-
therapy fraction in case of treatment completion according
to protocol. When a patient drops-out before the end of
treatment for any reasons other than DLT, he or she will
be replaced by an additional patient.
If there is a complete remission on re-evaluation FDG-
PET/CT-scan after chemoradiotherapy, a patient can dis-
cuss the possibility for a wait-and-see strategy off protocol
[43]. The decision to proceed to the next dose level of
evofosfamide will be made when the minimum post-
surgery or post-chemoradiotherapy (if no further surgery)
follow-up of each patient in a particular dose level is
30 days.
Patients are examined weekly during the treatment.
Follow-up starts directly after the end of treatment and
adverse events will be assessed at 1 and 4 weeks after
nCRT, right before surgery and one month after surgery.
Thereafter, follow-up visits will be planned every three
months in the first year after nCRT, twice in the second
year, and then yearly until a minimum follow-up time of
five years.
Discussion
Known and potential risks and benefits
The primary dose limiting toxicities of evofosfamide from
clinical studies have indicated more haematological tox-
icity than in monotherapeutic chemotherapy. Skin and
mucosal toxicities are common above doses of 240 mg/m2
[24, 25]. The mucosal toxicities increase with dose but are
still treatable with conservative approaches. The percent-
age of grade 3 esophagitis is expected to be higher in our
proposed study design than with the standard CROSS
treatment, but can be managed adequately (feeding tube,
parenteral nutrition).
Evofosfamide has not been tested in combination with
carboplatin, paclitaxel and radiotherapy before, so no
pharmacological interactions between these drugs are
known. A potential risk is that all three drugs can cause
mild haematological toxicity (reversible leukopenia, neu-
tropenia and/or lymphopenia) in some patients, but it is
not known if this effect will be amplified by combining
the drugs. Therefore we start with low dose levels of
evofosfamide in comparison to the maximum tolerated
doses in previous clinical studies. As an extra safety
measure, patients in the first cohort will only be in-
cluded when the previously included patient has finished
chemoradiotherapy.
We are aware that with our trial design, combining
evofosfamide with trimodality treatment, it will be diffi-
cult to determine the exact cause of potential adverse
events. An alternative design would be to only include
oesophageal cancer patients that receive either chemo-
therapy (carboplatin and/or paclitaxel) or radiotherapy.
However, this strategy currently is only applied in very
rare palliative cases. Moreover, the dose levels of chemo-
therapy and radiotherapy in a palliative setting are different
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than in a curative setting. Potentially curable patients
will always receive trimodality therapy and withholding
one of the treatment modalities to test the safety in
combination with evofosfamide in potentially curable
patients would, obviously, be very unethical, especially
since the effectiveness of evofosfamide in oesophageal
cancer is not proven yet. Hence, we believe that it is
essential to test evofosfamide in the setting as proposed
in this trial.
The benefit of this ‘window-of-opportunity’ trial is
that the clinical activity of evofosfamide in patients
with oesophageal cancer can be studied without being
compromised by previous or interfering treatments
[37]. Another benefit is that the combination therapy
might overcome resistance to conventional treatment
with chemoradiotherapy and creates a supra-additive
effect with increased tumour response. Patients with a
complete pathological response after neo-adjuvant treat-
ment eventually could opt for a wait-and-see strategy to
omit or postpone surgery.
Explorative image analysis
Hypoxia PET-tracer 18F-HX4 has been extensively used
at our institute in both pre-clinical and clinical studies.
It is shown that the tracer is not associated with any
toxicity [31], has a stable uptake pattern [33], provides
complementary information to metabolic FDG imaging
[34], and has a good spatial stability in lung, head and
neck [29], and oesophageal cancer [36]. The design of
this trial enables us to study the hypoxic response based
on imaging biomarker 18F-HX4 and blood biomarkers
CAIX and OPN. This early response assessment will give
us insight into the anti-tumour activity of evofosfamide,
and can be used to define the optimal dose for future clin-
ical research.
Calais et al. showed previously that high FDG-uptake
regions at baseline identify tumour sub-volumes that are
at a greater risk of recurrence [44]. Therefore explorative
image analysis will be performed to visualize the spatial
correlation between the baseline FDG-uptake and 18F-
HX4 uptake first, and later investigate if the high uptake
regions correlate with the patterns of residual disease.
Also the correlation between 18F-HX4-imaging and hyp-
oxia blood biomarkers CAIX and OPN will be evaluated.
Predictive models of outcome (e.g. pathological response,
survival) will be developed based on a so-called Radiomics
analysis. Radiomics is the extraction of a large number of
quantitative intensity, shape and textural features from
both CT and PET images [45]. It was shown that Radio-
mics features have prognostic value in both lung and head
and neck cancer [46–48]. The additional value of Radio-
mics features in response prediction of oesophageal cancer
patients is currently under investigation [49–51].
Another phase II clinical study currently investigates the
effect of tumour hypoxia on the response to standard che-
moradiation, by visualizing hypoxia with 18F-HX4-imaging
before treatment and two weeks after the start of treat-
ment (NCT02584400). Since the HX4-scanning settings
are identical, the imaging data of both studies provide
complementary information about the behaviour and in-
fluence of tumour hypoxia in oesophageal cancer treat-
ment. All of this together may be of additional value to
better stratify patients in the future [52], by identifying
patients who would benefit from hypoxia-selective treat-
ment, such as evofosfamide, already in an early stage.
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